文献速递急性肾损伤

替格列汀与恩格列净减轻铁死亡介导的急性肾小管损伤

Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本研究探讨DPP4抑制剂替格列汀(TG)和SGLT2抑制剂恩格列净(EMPA)是否通过抑制铁死亡保护肾小管细胞。体外实验显示铁死亡抑制剂可阻止叶酸和肌红蛋白诱导的HK-2细胞死亡,TG和EMPA均减少erastin诱导的细胞死亡和脂质过氧化。体内实验表明TG改善叶酸和甘油诱导的AKI模型肾功能、减轻小管损伤和炎症、保留GPX4表达,EMPA在横纹肌溶解相关AKI中显示类似保护作用。

要点

  • 铁死亡是叶酸和肌红蛋白诱导肾小管细胞死亡的关键机制
  • TG和EMPA通过减少脂质过氧化抑制铁死亡介导的肾小管损伤
  • TG在叶酸和甘油诱导AKI模型中改善肾功能并保留GPX4表达

核心结论

  • TG和EMPA在铁死亡介导的AKI模型中减轻肾小管细胞死亡和肾损伤,可能通过减少脂质过氧化实现。
  • 铁死亡抑制可能是DPP4和SGLT2抑制剂肾脏保护作用的潜在机制。

研究设计与样本

  • 体外研究:HK-2细胞预处理的凋亡、坏死性凋亡或铁死亡抑制剂后暴露于叶酸或肌红蛋白,评估TG和EMPA对erastin、叶酸和肌红蛋白诱导损伤的影响。
  • 体内研究:TG在叶酸和甘油诱导AKI模型中测试,EMPA在甘油诱导AKI模型中测试,评估肾功能、小管损伤、炎症和GPX4表达。

主要发现

  • Ferrostatin-1(铁死亡抑制剂)而非z-VAD-FMK或necrostatin-1s可预防叶酸和肌红蛋白诱导的体外细胞死亡。
  • TG和EMPA均显著减少erastin诱导的细胞死亡和脂质过氧化。
  • TG减轻叶酸和肌红蛋白诱导的细胞死亡和脂质过氧化,EMPA改善肌红蛋白模型的细胞活力和减少脂质过氧化。
  • 体内TG改善肾功能、减少小管损伤和炎症、保留GPX4表达,EMPA在横纹肌溶解相关AKI中显示类似保护效果。
  • DPP4与NOX4共定位但不与NOX1共定位,TG处理破坏NOX4与DPP4的共定位。

临床怎么用

  • TG和EMPA可能通过抑制铁死亡为AKI预防提供潜在治疗策略。
  • 需进一步临床研究验证铁死亡抑制在AKI防治中的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ferroptosis is a key mechanism of tubular cell death in acute kidney injury (AKI), particularly in folic acid- and glycerol-induced models. Dipeptidyl peptidase 4 (DPP4) and sodium-glucose co-transporter 2 (SGLT2) inhibitors exhibit renoprotective effects beyond glucose lowering, and emerging evidence suggests both may suppress ferroptosis. We hypothesized that teneligliptin (TG) and empagliflozin (EMPA) protect tubular cells from ferroptosis-mediated injury by reducing lipid peroxidation. METHODS: HK-2 cells were pretreated with inhibitors of apoptosis (z-VAD-FMK), necroptosis (necrostatin-1s) or ferroptosis (ferrostatin-1) and then exposed to folic acid or myoglobin. The effects of TG on erastin-, folic acid- and myoglobin-induced injury and of EMPA on erastin- and myoglobin-induced injury were evaluated using cell viability and lipid peroxidation assays. In vivo, TG was tested in folic acid- and glycerol-induced AKI models and EMPA in the glycerol-induced AKI model. Renal function, tubular injury, inflammation and glutathione peroxidase 4 (GPX4) expression were assessed. Localization of DPP4, nicotinamide adenine dinucleotide phosphate oxidase 1 (NOX1), NOX4 and megalin in the kidney was analysed by immunostaining. RESULTS: Ferrostatin-1, but not z-VAD-FMK or necrostatin-1s, prevented folic acid- and myoglobin-induced cell death in vitro. Both TG and EMPA significantly reduced erastin-induced cell death and lipid peroxidation. TG also attenuated cell death and lipid peroxidation in folic acid- and myoglobin-induced injury. EMPA improved viability and reduced lipid peroxidation in the myoglobin model. In vivo, TG improved renal function, reduced tubular damage and inflammation and preserved GPX4 expression. EMPA showed similar protective effects in rhabdomyolysis-associated AKI. DPP4 co-localized with NOX4 but showed no co-localization with NOX1. TG treatment disrupted the co-localization of NOX4 with DPP4. CONCLUSION: TG and EMPA attenuate tubular cell death and kidney injury in ferroptosis-mediated AKI models, potentially through the reduction of lipid peroxidation. These findings highlight ferroptosis suppression as a potential mechanism underlying their renoprotective effects in AKI prevention.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ema C, Iwakura T, Tsuji N, et al. Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury. Nephrol Dial Transplant. 2026. PMID: 41042250. doi:10.1093/ndt/gfaf203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。